Nuacht

Targeted Oncology59 nóiméad
Adjuvant Nivolumab Shows Sustained Benefit in Esophageal/GEJ Cancer
Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.